课题基金 / 基金详情

PHASE I/II OPEN LABEL EVALUATION OF NITAZOXANIDE CRYPTOSPORIDIOSIS IN AIDS

PHASE I/II OPEN LABEL EVALUATION OF NITAZOXANIDE CRYPTOSPORIDIOSIS IN AIDS
硝唑尼特隐孢子虫病治疗艾滋病的 I/II 期开放标签评估
批准号:
6113997
负责人:
ROSEMARY SOAVE
金额:
$7.95万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-01 至 1999-11-30

项目摘要

项目成果

ROSEMARY SOAVE的其他基金

相似基金

相关文献

中文摘要
翻译
本研究的目的是确定硝唑尼特在艾滋病相关隐孢子虫腹泻患者中的药代动力学,评价其安全性和有效性,并测定重复给药后的稳态血药浓度。另一个目的是评估通过d-木糖吸收试验确定的吸收不良、硝唑尼特血药浓度和疗效之间的关系。进度报告和调查结果摘要:在此期间没有新的科目入学。三名最初在I/II阶段研究中登记的受试者在同情维持的基础上继续接受NTZ治疗,并保持改善。结果将继续进行分析。
英文摘要
The objectives of this study are to determine the pharmacokinetics and assess safety and efficacy of nitazoxanide in patients with AIDS-related cryptosporidial diarrhea, and determine steady state concentrations of nitazoxanide following repeated dosing. Another objective is to assess the relationship between malabsorption, as determined by the d-xylose absorption test, nitazoxanide blood levels, and efficacy. Progress report and summary of findings: No new subjects were enrolled during this period. Three subjects originally enrolled in the Phase I/II study who continued NTZ therapy on a compassionate maintenance basis were followed and remained improved. Results continue to be analyzed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IMMUNOPATHOGENESIS OF CRYPTOSPORIDIOSIS
SAFETY & EFFICACY OF CLARITHROMYCIN FOR AIDS-RELATED CRYPTOSPORIDIAL DIARRHEA
PHASE I/II OPEN LABEL EVALUATION OF NITAZOXANIDE CRYPTOSPORIDIOSIS IN AIDS
IMMUNOPATHOGENESIS OF CRYPTOSPORIDIOSIS
国内基金
海外基金
人类和非人灵长类人隐孢子虫(Cryptosporidium hominis)的人兽共患传播机制研究
  • 批准号:
    U1404327
  • 项目类别:
    联合基金项目
  • 资助金额:
    30.0万元
  • 批准年份:
    2014
  • 负责人:
    朱惠丽
  • 依托单位: